Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Immunothrombolysis: deCoding neutrophiL Engagement in Active thrombus Resolution

Objetivo

Thrombosis remains a leading global cause of morbidity and mortality. In this process inflammation has been recognised as central driver besides platelets and coagulation. My work and that of others has defined thromboinflammation, the paradigm in which neutrophil–coagulation crosstalk drives vascular occlusions in the microvasculature and macrovasculature.

Recently, I introduced a previously unrecognized and paradigm-shifting concept: Neutrophils do not cease to act once a thrombus is formed. Instead, they continuously infiltrate established clots and acquire thrombolytic properties, directly promoting thrombus-resolution. I have termed this novel process immunothrombolysis, representing the conceptual opposite to thromboinflammation. A neutrophil-driven program of endogenous thrombus-clearance challenges one of the most entrenched assumptions in vascular biology. This has profound implications: If the underlying cellular, molecular and temporal mechanisms of immunothrombolysis can be harnessed, the immune-balance could artificially be tipped early towards endogenous thrombus resolution.
I hypothesize that neutrophil–coagulation interplay exerts stage-dependent, temporo-dynamically opposing effects, culminating in immunothrombolysis. To establish this new principle, I will:
1) Map the spatio-temporo-dynamic trajectories of continuous neutrophil infiltration, identifying the time and site where the switch from thromboinflammation to immunothrombolysis
2) Define the molecular triggers that reprogram neutrophils into a thrombolytic phenotype driving immunothrombolysis in the macrovasculature
3) Identify the molecular switches that induce endogenous microvascular thrombo-resolution to allow microvascular recanalyzation

This project could redefine thrombosis biology and pioneer endogenous immune-modulation for thrombus resolution, thereby reducing systemic therapeutic bleeding risks.

Ámbito científico (EuroSciVoc)

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-ERC - HORIZON ERC Grants

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) ERC-2026-STG

Ver todos los proyectos financiados en el marco de esta convocatoria

Institución de acogida

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Aportación neta de la UEn
€ 0,00
Dirección
GESCHWISTER SCHOLL PLATZ 1
80539 Planegg
Alemania
Región
Bayern Oberbayern München, Kreisfreie Stadt
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 1 499 837,00

Beneficiarios (2)